Download Editorials Published July 1, 2001

Editorials Published July 1, 2001 - June 30, 2004
Berry, J.D. Focus on Filamentous Phage Biology, The Germinal Centre Newsletter, Summer 2004.
http://www.icid.ca/ICID/ICID_NEWSLETTER.aspx
Chan C and Zhanel GG. Myths and reality in the treatment of lower respiratory tract infections. The Chronicle of
Cardiovascular and Internal Medicine 2001;October 8-13.
Chan CKN, Shibl A, Memish Z and Zhanel GG. Community acquired pneumonia (CAP): An update. Journal of
Chemotherapy 2001;13(Suppl 1):23-27.
Embree JE. Assessing immunization programs. Can J Infect Dis 13:224-225, 2002.
Embree JE. Ethics in research: Immunization and autism links. Paediatr & Child Health 9:373-372, 2004.
Embree JE. Immunization and autism links: Ethics in research. Can J Infect Dis 15: 73-74, 2004.
Embree JE. Reflections. Can J Infect Dis 12:269-270, 2001.
Gin AS and Zhanel GG. Antibiotic resistance: Playing the end game. Canadian Pharmaceutical Journal 2001;6:2-8.
Hammond, GW. Editorial: Immunization Must Be Safe or We'll All Be Sorry. Can J. Inf. Dis. Vol 12 No
1 January/February 2001, 11-12.
Hook EW, Peeling RW. Syphilis control: a continuing challenge. N Eng J Med 351:122-124, 2004.
Khaliq Y and Zhanel GG. Fluoroquinolone-induced tendinopathy: A critical review of the literature. Clinical
Infectious Diseases 2003;36:1404-1410.
Law BJ. Chickenpox vaccination, not chickenpox should be routine for Canadian children. CMAJ 2001;
164:1454-5.(Editorial requested by the editors of CMAJ).
MacDonald N, Embree JE, Access to vaccines: A call to action. Can J Infect Dis 14:9-10, 2003 and
Paediatrics and Child Health 8:11-12, 2003.
Markowsky MJ, Smith KK, Ariano RE, Zhanel GG Gin AS. An assessment of vancomycin use in 2 tertiary care
hospitals. Canadian Journal of Hospital Pharmacy 2004;57:150-157.
Nicolle, L.E. A new society (editorial) Can Jour Infect Dis 2002; 13:280-281.
Nicolle, L.E. A SARS Commentary (editorial) Can Jour Infect Dis 2003; 14:145-146.
Nicolle, L.E. Experiencing West Nile virus (editorial). Can Jour Infect Dis 2003; 14:75-76
Nicolle, L.E. Food for Thought (editorial). Can Jour Infect Dis 2002; 13:155-156.
Nicolle, L.E. Infection control in acute care facilities: Evidence based patient safety (editorial). Can J
Infect Dis 2001; 12:131-132.
Nicolle, L.E. Rabies: Still with us (editorial) Can Jour Infect Dis 2002; 13:83-84.
Nicolle, LE. SARS Safety and Science (editorial) Can Jour Anaesthesia 2003; 50: 983-988.
Nicolle, LE. Smallpox 2003 (editorial) Can Jour Infect Dis 2003; 14:247-248.
Nicolle, LE. Witnesses (editorial) Can Jour Infect Dis 2003; 14: 310.
Noreddin A and Zhanel GG. Pharmacokinetics and pharmacodynamics of respiratory fluoroquinolones. Current
Opinions in Pharmacology 2001;1(5):459-463.
Rzeszutek M, Wierzbowski A, Conly J, Bishai W, Hoban D and Zhanel GG. A Review of Clinical Failures
Involving Macrolide-Resistant Streptococcus pneumoniae. International Journal of Antimicrobial Agents
2004;24:95-104.
Sande MA, Ronald A. Treatment of HIV/AIDS: Do The Dilemmas Only Increase? JAMA. 2004 July
14;292(2):266-268.
Smith HJ, Nichol K, Hoban DJ and Zhanel GG. Stretching the mutant prevention concentration (MPC) beyond
its limits. Journal of Antimicrobial Chemotherapy 2003;51(6):1323-1325.
Smith HJ, Nichol KA, Hoban DJ and Zhanel GG. Dual activity of fluoroquinolones against Streptococcus
pneumoniae: The facts behind the claims. Journal of Antimicrobial Chemotherapy 2002;49:893-895.
Smith HJ, Nichol KA, Hoban DJ and Zhanel GG. Dual activity of fluoroquinolones against Streptococcus
pneumoniae: The facts behind the claims. Journal of Antimicrobial Chemotherapy 2003;51(2):63-67 (Reply to
letter).
Wang, G. ASM News – Journal Highlights of “ Detection in Escherichia coli of the genes encoding the
major virulence factors, the genes defining the O157:H7 serotype, and components of the type 2 Shiga
toxin family by multiplex PCR.” Vol 68 (12): 619, Dec. 2002.
Zhanel GG and Hoban DJ. Ketolides in the treatment of respiratory infections. Expert Opinion in
Pharmacotherapy 2002;3(3):277-297.
Zhanel GG and Noreddin AM. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates: In vitro
models. Annals of Pharmacotherapy 2003;37:1331-1334.
Zhanel GG and Rubinstein E. Extended release ciprofloxacin (XR). Invited commentary. Drugs Aging 2004;
21(1); 65-66.
Zhanel GG, Dueck M, Hoban DJ, Vercaigne L, Embil J, Gin AS, Karlowsky JA. Macrolides and Ketolides: A review
focusing on respiratory infections. Drugs 2001;61 (4):443-498.
Zhanel GG, Embil J. Tendinopathy and fluoroquinolones: What is the risk ? Journal of Respiratory Diseases
2004;25:227 (invited letter).
Zhanel GG, Ennis K, Vercaigne L, Gin AS, Embil J, and Hoban DJ. Critical review of fluoroquinolones: Focus on
respiratory infections. Drugs 2002;62(1):13-59.
Zhanel GG, Hisanaga T, Nichol K, Wierzbowski A and Hoban DJ. Emerging Treatments for Macrolide
Resistant Bacteria. Expert Opinion on Emerging Drugs 2003;8:297-321.
Zhanel GG, Hoban DJ and Chan CK. Resistance to levofloxacin and failure of pneumococcal pneumonia. New
England Journal of Medicine 2002;347:66.
Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Karlowsky J, Embil J, Gin AS and Hoban DJ. The
glycylcyclines: A critical review. Drugs 2004;64(1);63-88.
Zhanel GG, Schroeder K, Vercaigne L, Gin AS, Embil J and Hoban DJ. A critical review of oxazolidinones: A
replacement for glycopeptides? Canadian Journal of Infectious Diseases 2001;12(6):379-90.
Zhanel GG, Walters M, Noreddin A, Vercaigne L, Wierzbowski A, Embil J, Gin AS and Hoban DJ. The ketolides: A
critical review. Drugs 2002; 62(12):1771-1804.
Zhanel GG, Wierzbowski A, Hisanaga T and Hoban DJ. The use of ketolides in the treatment of upper
respiratory tract infections Clinical Infectious Diseases Reports 2004;6:191-199.
Zhanel GG. Cephalosporins in URTI’s: Targeting the common pathogens. Canadian Journal of Diagnosis 2002;
March (Supplement):1-9.
Zhanel GG. In-vitro activity of garenoxacin, a novel des-(F) 6 fluoroquinolone. Clinical Microbiology Newsletter
2004;2:3-11.
Zhanel GG. Pharmacokinetic and pharmacodynamic factors when selecting antibiotic therapy: Focus on respiratory
infections. Current Infectious Disease Reports: Antimicrobial Agents 2001;3:29-34.
Zhanel GG. Regional considerations in the management of anthrax exposure and infection. Drugs and therapy
perspectives 2001;17 (24):10 (invited commentary).
Zhanel GG. The role of macrolides in the treatment of community acquired respiratory illness. Medical Tribune
2003;2:1-6.